Skip to main content

Caribou Biosciences, Inc.

CRBU
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001619856

No open-market purchases or sales by Caribou Biosciences, Inc. insiders were filed in the last 90 days; 137 institutions reported holding it in 13F filings for Q2 2026, worth $84.8M in total; Maverick Capital is the only superinvestor holding it.

Q3 2022 vs. Q2 2022

How the institutions holding Caribou Biosciences, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of CRBU: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders120113−7
Shares37.3M43.2M+5.90M (+15.8%)
Value$203.0M$456.8M+$253.8M (+125.0%)

New holders (14)

Institutions that held Caribou Biosciences, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to CRBU in Q3 2022
InstitutionSharesValue% of portfolio
Elmwood Wealth Management, Inc.2,364,240$24.9M12.45%
Norges Bank246,500$2.60M0.00%
Rafferty Asset Management, LLC131,239$1.39M0.01%
BNP Paribas Arbitrage, SA83,101$876.7K0.00%
RMB Capital Management, LLC74,787$789.0K0.03%
Ameriprise Financial Inc38,192$403.0K0.00%
Kettle Hill Capital Management, LLC37,200$392.0K0.09%
Jane Street Group, LLC17,313$183.0K0.00%
Teacher Retirement System of Texas15,941$168.0K0.00%
Principal Financial Group Inc12,736$134.0K0.00%
Amundi4,501$48.0K0.00%
Russell Investments Group, Ltd.1,716$18.0K0.00%
Allspring Global Investments Holdings, LLC676$7.00K0.00%
China Universal Asset Management Co., Ltd.570$6.00K0.00%

Sold out (21)

Institutions that held Caribou Biosciences, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.